{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-26-000003","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.352993+00:00","generated_at":"2026-05-16T05:27:12.788546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84","bullets":["Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.","GAAP EPS $2.45 Q4 (+111%), full year $14.23 (+88%); non-GAAP EPS full year $21.84 (+10%).","Recorded $1.2B Otezla intangible impairment due to IRA Medicare price setting.","Free cash flow $8.1B full year vs $10.4B prior, down on working capital timing.","18 products achieved record full-year sales; 14 exceeded $1B in annual sales."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-26-000003","json":"https://secwatch.observer/filing/0000318154-26-000003.json","markdown":"https://secwatch.observer/filing/0000318154-26-000003.md","text":"https://secwatch.observer/filing/0000318154-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/0000318154-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20260203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:27:12.788546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}